The NGF metabolic pathway in the CNS and its dysregulation in down syndrome and Alzheimer’s disease

Current Alzheimer Research

Volumn 13, Issue 1, 2016, Pages 53-67

  Iulita, M Florencia ^a   Cuello, A Claudio ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer s disease; Cholinergic neurons; Down syndrome; Inflammation; Matrix metallo protease 9; Nerve growth factor; Neuroserpin; Neurotrophins; NGF metabolism; Plasminogen; Tissue inhibitor of metallo proteases; Tissue plasminogen activator

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; GELATINASE B; NERVE GROWTH FACTOR; NEUROSERPIN; NEUROTROPHIN; PLASMIN; PLASMINOGEN; PROTEIN TYROSINE KINASE A; TISSUE PLASMINOGEN ACTIVATOR;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; ATTENTION; BRAIN CORTEX; CELL METABOLISM; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM TUMOR; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; COGNITION; DEMENTIA; DOWN SYNDROME; EXTRACELLULAR SPACE; GLUCOSE METABOLISM; GLYCOSYLATION; HUMAN; IMMUNOREACTIVITY; LEARNING; LONG TERM POTENTIATION; MEMORY; METABOLISM; NERVE CELL GROWTH; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; ANIMAL; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; CENTRAL NERVOUS SYSTEM; DOWN SYNDROME; HUMANS; NERVE GROWTH FACTOR;

EID: 84953455893     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205012666150921100030     Document Type: Article

References (211)

1. Bibel M, Barde YA. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev 14 (23): 2919-2937 (2000).
2. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. Clin Sci (Lond) 110 (2): 175-191 (2006).
3. Chao MV. Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci 4 (4): 299-309 (2003).
4. Kaplan DR, Miller FD. Neurotrophin signal transduction in the nervous system. Curr Opin Neurobiol 10 (3): 381-391 (2000).
5. Thoenen H. Neurotrophins and neuronal plasticity. Science 270 (5236): 593-598 (1995).
6. Levi-Montalcini R, Hamburger V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J Exp Zool 116 (2): 321-361 (1951).
7. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24: 1217-1281 (2001).
8. Cuello AC. Effects of trophic factors on the CNS cholinergic phenotype. Prog Brain Res 109 347-358 (1996).
9. Hefti F, Will B. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for Alzheimer's disease. J Neural Transm Suppl 24: 309-315 (1987).
10. Etienne P, Robitaille Y, Wood P, Gauthier S, Nair NP, Quirion R. Nucleus basalis neuronal loss, neuritic plaques and choline acetyltransferase activity in advanced Alzheimer's disease. Neuroscience 19(4): 1279-1291 (1986).
11. Pearson RC, Sofroniew MV, Cuello AC, Powell TP, Eckenstein F, Esiri MM, et al. Persistence of cholinergic neurons in the basal nucleus in a brain with senile dementia of the Alzheimer's type demonstrated by immunohistochemical staining for choline acetyltransferase. Brain Res 289(1-2): 375-379 (1983).
12. Mufson EJ, Bothwell M, Kordower JH. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. Exp Neurol 105 (3):221-232 (1989).
13. Mufson EJ, Ma SY, Cochran EJ, Bennett DA, Beckett LA, Jaffar S, et al. Loss of nucleus basalis neurons containing trkA immunoreactivity in individuals with mild cognitive impairment and early Alzheimer's disease. J Comp Neurol 427(1): 19-30 (2000).
14. Vogels OJ, Broere CA, ter Laak HJ, ten Donkelaar HJ, Nieuwenhuys R, Schulte BP. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol Aging 11(1): 3-13 (1990).
15. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215 (4537): 1237-1239 (1982).
16. Casanova MF, Walker LC, Whitehouse PJ, Price DL. Abnormalities of the nucleus basalis in Down's syndrome. Ann Neurol 18(3): 310-313 (1985).
17. Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol 10(3): 185-207 (1984).
18. Prince M, Prina M, Guerchet M. World Alzheimer Report 2013. Journey of Caring. An analysis of long-term care for dementia. Alzheimer's Dis Int 1-33 (2013).
19. Burns A, Iliffe S. Alzheimer's disease. BMJ 338 B:158 (2009).
20. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin 64: 146-148 (1907).
21. Terry RD. The Fine Structure of Neurofibrillary Tangles in Alzheimer's Disease. J Neuropathol Exp Neurol 22: 629-642 (1963).
22. Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 2 (6): 357-369 (1984).
23. Braak H, Braak E. Neuropathological stageing of Alzheimerrelated changes. Acta Neuropathol 82(4): 239-259 (1991).
24. Arendt T, Taubert G, Bigl V, Arendt A. Amyloid deposition in the nucleus basalis of Meynert complex: a topographic marker for degenerating cell clusters in Alzheimer's disease. Acta Neuropathol 75(3): 226-232 (1988).
25. Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 9(11): 1118-1127 (2010).
26. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7(3): 280-292 (2011).
27. Jack CR, Jr., Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9(1): 119-128 (2010).
28. Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 12(2): 207-216 (2013).
29. Teller JK, Russo C, DeBusk LM, Angelini G, Zaccheo D, Dagna-Bricarelli F, et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med 2(1): 93-95 (1996).
30. Leverenz JB, Raskind MA. Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 150(2): 296-304 (1998).
31. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ. Sequence of deposition of heterogeneous amyloid betapeptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis 3(1): 16-32 (1996).
32. Mori C, Spooner ET, Wisniewsk KE, Wisniewski TM, Yamaguch H, Saido TC, et al. Intraneuronal Abeta42 accumulation in Down syndrome brain. Amyloid 9(2): 88-102 (2002).
33. Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol 17(3): 278-282 (1985).
34. Handen BL, Cohen AD, Channamalappa U, Bulova P, Cannon SA, Cohen WI, et al. Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B. Alzheimers Dement 8(6): 496-501 (2012).
35. Gardiner K, Davisson M. The sequence of human chromosome 21 and implications for research into Down syndrome. Genom Biol 1(2): REVIEWS0002 (2000).
36. Cheon MS, Dierssen M, Kim SH, Lubec G. Protein expression of BACE1, BACE2 and APP in Down syndrome brains. Amino Acids 35(2): 339-343 (2008).
37. Hefti F. Is Alzheimer disease caused by lack of nerve growth factor? Ann Neurol 13(1): 109-110 (1983).
38. Appel SH. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 10(6): 499-505 (1981).
39. Goedert M, Fine A, Hunt SP, Ullrich A. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Brain Res 387(1): 85-92 (1986).
40. Jette N, Cole MS, Fahnestock M. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Brain Res Mol Brain Res 25(3-4): 242-250 (1994).
41. Fahnestock M, Scott SA, Jette N, Weingartner JA, Crutcher KA. Nerve growth factor mRNA and protein levels measured in the same tissue from normal and Alzheimer's disease parietal cortex. Brain Res Mol Brain Res 42(1): 175-178 (1996).
42. Pedraza CE, Podlesniy P, Vidal N, Arevalo JC, Lee R, Hempstead B, et al. Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol 166(2): 533-543 (2005).
43. Fahnestock M, Michalski B, Xu B, Coughlin MD. The precursor pro-nerve growth factor is the predominant form of nerve growth factor in brain and is increased in Alzheimer's disease. Mol Cell Neurosci 18 (2): 210-220 (2001).
44. Hamburger V, Levi-Montalcini R. Proliferation, differentiation and degeneration in the spinal ganglia of the chick embryo under normal and experimental conditions. J Exp Zool 111(3): 457-501 (1949).
45. Cohen S, Levi-Montalcini R, Hamburger V. A nerve growthstimulating factor isolated from sarcom as 37 and 180. Proc Natl Acad Sci USA 40(10): 1014-1018 (1954).
46. Levi-Montalcini R, Cohen S. In vitro and in vivo effects of a nerve growth-stimulating agent isolated from snake venom. Proc Natl Acad Sci USA 42(9): 695-699 (1956).
47. Cohen S, Levi-Montalcini R. A nerve growth-stimulating factor isolated from snake venom. Proc Natl Acad Sci USA 42 (9): 571-574 (1956).
48. Levi-Montalcini R, Dal Toso R, della Valle F, Skaper SD, Leon A. Update of the NGF saga. J Neurol Sci 130(2): 119-127 (1995).
49. Levi-Montalcini R, Skaper SD, Dal Toso R, Petrelli L, Leon A. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci 19(11): 514-520 (1996).
50. Skaper SD. Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions. Mol Neurobiol 24(1-3): 183-199 (2001).
51. Chen EY, Mufson EJ, Kordower JH. TRK and p75 neurotrophin receptor systems in the developing human brain. J Comp Neurol 369(4): 591-618 (1996).
52. Kordower JH, Mufson EJ. Nerve growth factor receptorimmunoreactive neurons within the developing human cortex. J Comp Neurol 323(1): 25-41 (1992).
53. von Bartheld CS, Heuer JG, Bothwell M. Expression of nerve growth factor (NGF) receptors in the brain and retina of chick embryos: comparison with cholinergic development. J Comp Neurol 310(1): 103-129 (1991).
54. Frade JM, Bovolenta P, Martinez-Morales JR, Arribas A, Barbas JA, Rodriguez-Tebar A. Control of early cell death by BDNF in the chick retina. Development 124(17): 3313-3320 (1997).
55. Gibbs RB, Pfaff DW. In situ hybridization detection of trkA mRNA in brain: distribution, colocalization with p75NGFR and up-regulation by nerve growth factor. J Comp Neurol 341(3): 324-339 (1994).
56. Holtzman DM, Li Y, Parada LF, Kinsman S, Chen CK, Valletta JS, et al. p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron 9(3): 465-478 (1992).
57. Pioro EP, Cuello AC. Distribution of nerve growth factor receptorlike immunoreactivity in the adult rat central nervous system. Effect of colchicine and correlation with the cholinergic system--II. Brainstem, cerebellum and spinal cord. Neuroscience 34(1): 89-110 (1990).
58. Sobreviela T, Clary DO, Reichardt LF, Brandabur MM, Kordower JH, Mufson EJ. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol 350(4): 587-611 (1994).
59. Drachman DA, Leavitt J. Human memory and the cholinergic system. A relationship to aging? Arch Neurol 30(2): 113-121 (1974).
60. Deutsch JA. The cholinergic synapse and the site of memory. Science 174(4011): 788-794 (1971).
61. Bartus RT, Dean RL, 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 217 (4558):408-414 (1982).
62. Mesulam MM, Mufson EJ, Levey AI, Wainer BH. Cholinergic innervation of cortex by the basal forebrain: cytochemistry and cortical connections of the septal area, diagonal band nuclei, nucleus basalis (substantia innominata), and hypothalamus in the rhesus monkey. J Comp Neurol 214(2): 170-197 (1983).
63. Mesulam MM, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Ch1-Ch6). Neuroscience 10(4): 1185-1201 (1983).
64. Seiler M, Schwab ME. Specific retrograde transport of nerve growth factor (NGF) from neocortex to nucleus basalis in the rat. Brain Res 300(1): 33-39 (1984).
65. Schwab ME, Otten U, Agid Y, Thoenen H. Nerve growth factor (NGF) in the rat CNS: absence of specific retrograde axonal transport and tyrosine hydroxylase induction in locus coeruleus and substantia nigra. Brain Res 168(3): 473-483 (1979).
66. Korsching S, Auburger G, Heumann R, Scott J, Thoenen H. Levels of nerve growth factor and its mRNA in the central nervous system of the rat correlate with cholinergic innervation. EMBO J 4(6): 1389-1393 (1985).
67. Conner JM, Varon S. Distribution of nerve growth factor-like immunoreactive neurons in the adult rat brain following colchicine treatment. J Comp Neurol 326(3): 347-362 (1992).
68. Sofroniew MV, Pearson RC, Eckenstein F, Cuello AC, Powell TP. Retrograde changes in cholinergic neurons in the basal forebrain of the rat following cortical damage. Brain Res 289(1-2): 370-374 (1983).
69. Sofroniew MV, Galletly NP, Isacson O, Svendsen CN. Survival of adult basal forebrain cholinergic neurons after loss of target neurons. Science 247(4940): 338-342 (1990).
70. Figueiredo BC, Skup M, Bedard AM, Tetzlaff W, Cuello AC. Differential expression of p140trk, p75NGFR and growthassociated phosphoprotein-43 genes in nucleus basalis magnocellularis, thalamus and adjacent cortex following neocortical infarction and nerve growth factor treatment. Neuroscience 68(1): 29-45 (1995).
71. Venero JL, Knusel B, Beck KD, Hefti F. Expression of neurotrophin and trk receptor genes in adult rats with fimbria transections: effect of intraventricular nerve growth factor and brain-derived neurotrophic factor administration. Neuroscience 59(4): 797-815 (1994).
72. Pongrac JL, Rylett RJ. NGF-induction of the expression of ChAT mRNA in PC12 cells and primary cultures of embryonic rat basal forebrain. Brain Res Mol Brain Res 62(1): 25-34 (1998).
73. Auld DS, Mennicken F, Quirion R. Nerve growth factor rapidly induces prolonged acetylcholine release from cultured basal forebrain neurons: differentiation between neuromodulatory and neurotrophic influences. J Neurosci 21(10): 3375-3382 (2001).
74. Oosawa H, Fujii T, Kawashima K. Nerve growth factor increases the synthesis and release of acetylcholine and the expression of vesicular acetylcholine transporter in primary cultured rat embryonic septal cells. J Neurosci Res 57(3): 381-387 (1999).
75. Mobley WC, Rutkowski JL, Tennekoon GI, Buchanan K, Johnston MV. Choline acetyltransferase activity in striatum of neonatal rats increased by nerve growth factor. Science 229(4710): 284-287 (1985).
76. Debeir T, Saragovi HU, Cuello AC. A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat. Proc Natl Acad Sci USA 96 (7): 4067-4072 (1999).
77. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transections. J Neurosci 6(8): 2155-2162 (1986).
78. Williams LR, Varon S, Peterson GM, Wictorin K, Fischer W, Bjorklund A, et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 83(23): 9231-9235 (1986).
79. Garofalo L, Ribeiro-da-Silva A, Cuello AC. Nerve growth factorinduced synaptogenesis and hypertrophy of cortical cholinergic terminals. Proc Natl Acad Sci USA 89(7): 2639-2643 (1992).
80. Garofalo L, Cuello AC. Nerve growth factor and the monosialoganglioside GM1: analogous and different in vivo effects on biochemical, morphological, and behavioral parameters of adult cortically lesioned rats. Exp Neurol 125(2): 195-217 (1994).
81. Liberini P, Pioro EP, Maysinger D, Ervin FR, Cuello AC. Longterm protective effects of human recombinant nerve growth factor and monosialoganglioside GM1 treatment on primate nucleus basalis cholinergic neurons after neocortical infarction. Neuroscience 53 (3): 625-637 (1993).
82. Garofalo L, Cuello AC. Pharmacological characterization of nerve growth factor and/or monosialoganglioside GM1 effects on cholinergic markers in the adult lesioned brain. J Pharmacol Exp Ther 272(2): 527-545 (1995).
83. Hu L, Cote SL, Cuello AC. Differential modulation of the cholinergic phenotype of the nucleus basalis magnocellularis neurons by applying NGF at the cell body or cortical terminal fields. Exp Neurol 143(1): 162-171 (1997).
84. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2(8000): 1403 (1976).
85. Bowen DM, Smith CB, White P, Davison AN. Neurotransmitterrelated enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 99(3): 459-496 (1976).
86. Perry EK, Gibson PH, Blessed G, Perry RH, Tomlinson BE. Neurotransmitter enzyme abnormalities in senile dementia. Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue. J Neurol Sci 34(2): 247-265 (1977).
87. Yates CM, Simpson J, Gordon A, Maloney AF, Allison Y, Ritchie IM, et al. Catecholamines and cholinergic enzymes in pre-senile and senile Alzheimer-type dementia and Down's syndrome. Brain Res 280(1): 119-126 (1983).
88. Hu L, Wong TP, Cote SL, Bell KF, Cuello AC. The impact of Abeta-plaques on cortical cholinergic and non-cholinergic presynaptic boutons in alzheimer's disease-like transgenic mice. Neuroscience 121(2): 421-432 (2003).
89. Bell KF, Ducatenzeiler A, Ribeiro-da-Silva A, Duff K, Bennett DA, Cuello AC. The amyloid pathology progresses in a neurotransmitter-specific manner. Neurobiol Aging 27 (11): 1644-1657 (2006).
90. Ferretti MT, Partridge V, Leon WC, Canneva F, Allard S, Arvanitis DN, et al. Transgenic mice as a model of pre-clinical Alzheimer's disease. Curr Alzheimer Res 8(1): 4-23 (2011).
91. Wong TP, Debeir T, Duff K, Cuello AC. Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes. J Neurosci 19(7): 2706-2716 (1999).
92. Jaffar S, Counts SE, Ma SY, Dadko E, Gordon MN, Morgan D, et al. Neuropathology of mice carrying mutant APP(swe) and/or PS1(M146L) transgenes: alterations in the p75(NTR) cholinergic basal forebrain septohippocampal pathway. Exp Neurol 170(2): 227-243 (2001).
93. Hernandez D, Sugaya K, Qu T, McGowan E, Duff K, McKinney M. Survival and plasticity of basal forebrain cholinergic systems in mice transgenic for presenilin-1 and amyloid precursor protein mutant genes. Neuroreport 12(7): 1377-1384 (2001).
94. Lewin GR, Rueff A, Mendell LM. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur J Neurosci 6(12): 1903-1912 (1994).
95. Eriksdotter Jonhagen M, Nordberg A, Amberla K, Backman L, Ebendal T, Meyerson B, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord 9(5): 246-257 (1998).
96. Tuszynski MH, Thal L, Pay M, Salmon DP, U HS, Bakay R, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med 11(5): 551-555 (2005).
97. Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement 10(5): 571-581 (2014).
98. Eriksdotter-Jonhagen M, Linderoth B, Lind G, Aladellie L, Almkvist O, Andreasen N, et al. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord 33(1): 18-28 (2012).
99. Ferreira D, Westman E, Eyjolfsdottir H, Almqvist P, Lind G, Linderoth B, et al. Brain changes in Alzheimer's disease patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis 43(3): 1059-1072 (2015).
100. Zabel BU, Eddy RL, Lalley PA, Scott J, Bell GI, Shows TB. Chromosomal locations of the human and mouse genes for precursors of epidermal growth factor and the beta subunit of nerve growth factor. Proc Natl Acad Sci USA 82 (2): 469-473 (1985).
101. Francke U, de Martinville B, Coussens L, Ullrich A. The human gene for the beta subunit of nerve growth factor is located on the proximal short arm of chromosome 1. Science 222 (4629): 1248-1251 (1983).
102. Scott J, Selby M, Urdea M, Quiroga M, Bell GI, Rutter WJ. Isolation and nucleotide sequence of a cDNA encoding the precursor of mouse nerve growth factor. Nature 302 (5908): 538-540 (1983).
103. Ebendal T, Larhammar D, Persson H. Structure and expression of the chicken beta nerve growth factor gene. EMBO J 5(7): 1483-1487 (1986).
104. Meier R, Becker-Andre M, Gotz R, Heumann R, Shaw A, Thoenen H. Molecular cloning of bovine and chick nerve growth factor (NGF): delineation of conserved and unconserved domains and their relationship to the biological activity and antigenicity of NGF. EMBO J 5(7): 1489-1493 (1986).
105. Ullrich A, Gray A, Berman C, Dull TJ. Human beta-nerve growth factor gene sequence highly homologous to that of mouse. Nature 303(5920): 821-825 (1983).
106. Selby MJ, Edwards R, Sharp F, Rutter WJ. Mouse nerve growth factor gene: structure and expression. Mol Cell Biol 7(9): 3057-3064 (1987).
107. Edwards RH, Selby MJ, Rutter WJ. Differential RNA splicing predicts two distinct nerve growth factor precursors. Nature 319(6056): 784-787 (1986).
108. Darling TL, Petrides PE, Beguin P, Frey P, Shooter EM, Selby M, et al. The biosynthesis and processing of proteins in the mouse 7S nerve growth factor complex. Cold Spring Harb Symp Quant Biol 48 Pt 1: 427-434 (1983).
109. Seidah NG, Benjannet S, Pareek S, Savaria D, Hamelin J, Goulet B, et al. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochem J 314(Pt 3): 951-960 (1996).
110. Bruno MA, Cuello AC. Activity-dependent release of precursor nerve growth factor, conversion to mature nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci USA 103(17): 6735-6740 (2006).
111. Mowla SJ, Pareek S, Farhadi HF, Petrecca K, Fawcett JP, Seidah NG, et al. Differential sorting of nerve growth factor and brainderived neurotrophic factor in hippocampal neurons. J Neurosci 19(6): 2069-2080 (1999).
112. Reinshagen M, Geerling I, Eysselein VE, Adler G, Huff KR, Moore GP, et al. Commercial recombinant human beta-nerve growth factor and adult rat dorsal root ganglia contain an identical molecular species of nerve growth factor prohormone. J Neurochem 74(5): 2127-2133 (2000).
113. Berger EA, Shooter EM. Evidence for pro-beta-nerve growth factor, a biosynthetic precursor to beta-nerve growth factor. Proc Natl Acad Sci USA 74(9): 3647-3651 (1977).
114. Varon S, Normura J, Shooter EM. Reversible dissociation of the mouse nerve growth factor protein into different subunits. Biochemistry 7(4): 1296-1303 (1968).
115. Angeletti RH, Bradshaw RA, Wade RD. Subunit structure and amino acid composition of mouse submaxillary gland nerve growth factor. Biochemistry 10(3): 463-469 (1971).
116. Greene LA, Shooter EM, Varon S. Enzymatic activities of mouse nerve growth factor and its subunits. Proc Natl Acad Sci USA 60(4): 1383-1388 (1968).
117. Varon S, Nomura J, Shooter EM. The isolation of the mouse nerve growth factor protein in a high molecular weight form. Biochemistry 6(7): 2202-2209 (1967).
118. Mobley WC, Schenker A, Shooter EM. Characterization and isolation of proteolytically modified nerve growth factor. Biochemistry 15(25): 5543-5552 (1976).
119. Esposito D, Patel P, Stephens RM, Perez P, Chao MV, Kaplan DR, et al. The cytoplasmic and transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor. J Biol Chem 276(35): 32687-32695 (2001).
120. Kahle P, Barker PA, Shooter EM, Hertel C. p75 nerve growth factor receptor modulates p140trkA kinase activity, but not ligand internalization, in PC12 cells. J Neurosci research 38(5): 599-606 (1994).
121. Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao MV. High-affinity NGF binding requires coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350(6320): 678-683 (1991).
122. Howe CL, Mobley WC. Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol 15(1): 40-48 (2005).
123. Howe CL, Valletta JS, Rusnak AS, Mobley WC. NGF signaling from clathrin-coated vesicles: evidence that signaling endosomes serve as a platform for the Ras-MAPK pathway. Neuron 32(5): 801-814 (2001).
124. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 350 (6314): 158-160 (1991).
125. Chao MV, Rajagopal R, Lee FS. Neurotrophin signalling in health and disease. Clin Sci (Lond) 110(2): 167-173 (2006).
126. Roux PP, Barker PA. Neurotrophin signaling through the p75 neurotrophin receptor. Prog Neurobiol 67(3): 203-233 (2002).
127. Taniuchi M, Schweitzer JB, Johnson EM, Jr. Nerve growth factor receptor molecules in rat brain. Proc Nat Acad Sci USA 83(6): 1950-1954 (1986).
128. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. Sortilin is essential for proNGF-induced neuronal cell death. Nature 427(6977): 843-848 (2004).
129. Lee R, Kermani P, Teng KK, Hempstead BL. Regulation of cell survival by secreted proneurotrophins. Science 294 (5548):1945-1948 (2001).
130. Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, et al. The nerve growth factor precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 89(3): 581-592 (2004).
131. Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, Clewes O, et al. Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J Biol Chem 284(27): 18424-18433 (2009).
132. Bresnahan PA, Leduc R, Thomas L, Thorner J, Gibson HL, Brake AJ, et al. Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J Cell Biol 111(6 Pt 2): 2851-2859 (1990).
133. Blochl A, Thoenen H. Characterization of nerve growth factor (NGF) release from hippocampal neurons: evidence for a constitutive and an unconventional sodium-dependent regulated pathway. Eur J Neurosci 7(6): 1220-1228 (1995).
134. Blochl A, Thoenen H. Localization of cellular storage compartments and sites of constitutive and activity-dependent release of nerve growth factor (NGF) in primary cultures of hippocampal neurons. Mol Cell Neurosci 7(3): 173-190 (1996).
135. Yepes M, Lawrence DA. Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system? Trends Cardiovasc Med 14(5): 173-180 (2004).
136. Miranda E, Lomas DA. Neuroserpin: a serpin to think about. Cell Mol Life Sci 63(6):709-722 (2006).
137. Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci 2(7): 502-511 (2001).
138. Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, et al. Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306(5695): 487-491 (2004).
139. Nagappan G, Zaitsev E, Senatorov VV, Jr., Yang J, Hempstead BL, Lu B. Control of extracellular cleavage of ProBDNF by high frequency neuronal activity. Proc Natl Acad Sci USA 106(4): 1267-1272 (2009).
140. Woo NH, Teng HK, Siao CJ, Chiaruttini C, Pang PT, Milner TA, et al. Activation of p75NTR by proBDNF facilitates hippocampal long-term depression. Nat Neurosci 8(8): 1069-1077 (2005).
141. Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, et al. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF. Nat Neurosci 11 (2):131-133 (2008).
142. Yang J, Siao CJ, Nagappan G, Marinic T, Jing D, McGrath K, et al. Neuronal release of proBDNF. Nat Neurosci 12(2): 113-115 (2009).
143. Barker PA. Whither proBDNF? Nat Neurosci 12(2):105-106 (2009).
144. An JJ, Gharami K, Liao GY, Woo NH, Lau AG, Vanevski F, et al. Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons. Cell 134(1): 175-187 (2008).
145. Allard S, Leon WC, Pakavathkumar P, Bruno MA, Ribeiro-da-Silva A, Cuello AC. Impact of the NGF maturation and degradation pathway on the cortical cholinergic system phenotype. J Neurosci 32(6): 2002-2012 (2012).
146. Tiveron C, Fasulo L, Capsoni S, Malerba F, Marinelli S, Paoletti F, et al. ProNGF\NGF imbalance triggers learning and memory deficits, neurodegeneration and spontaneous epileptic-like discharges in transgenic mice. Cell Death Differ 20(8): 1017-1030 (2013).
147. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. Cholinergic involvement in Alzheimer's disease. A link with NGF maturation and degradation. J Mol Neurosci 40(1-2): 230-235 (2010).
148. Cuello AC, Sofroniew MV. The anatomy of the CNS cholinergic neurons. Trends Neurosci 7 (3):74-78 (1984).
149. Bruno MA, Leon WC, Fragoso G, Mushynski WE, Almazan G, Cuello AC. Amyloid beta-induced nerve growth factor dysmetabolism in Alzheimer disease. J Neuropathol Exp Neurol 68(8): 857-869 (2009).
150. Fabbro S, Seeds NW. Plasminogen activator activity is inhibited while neuroserpin is up-regulated in the Alzheimer disease brain. J Neurochem 109(2): 303-315 (2009).
151. Ledesma MD, Da Silva JS, Crassaerts K, Delacourte A, De Strooper B, Dotti CG. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep 1(6): 530-535 (2000).
152. Ledesma MD, Abad-Rodriguez J, Galvan C, Biondi E, Navarro P, Delacourte A, et al. Raft disorganization leads to reduced plasmin activity in Alzheimer's disease brains. EMBO Rep 4(12): 1190-1196 (2003).
153. Rosenberg GA. Matrix metalloproteinases and their multiple roles in neurodegenerative diseases. Lancet Neurol 8(2): 205-216 (2009).
154. Rosenberg GA. Neurological diseases in relation to the blood-brain barrier. J Cereb Blood Flow Metab 32(7): 1139-1151 (2012).
155. Cuello AC, Bruno MA. The failure in NGF maturation and its increased degradation as the probable cause for the vulnerability of cholinergic neurons in Alzheimer's disease. Neurochem Res 32(6): 1041-1045 (2007).
156. Perez SE, He B, Muhammad N, Oh KJ, Fahnestock M, Ikonomovic MD, et al. Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice. Neurobiol Dis 41(2): 338-352 (2011).
157. Figueiredo BC, Hu L, Bedard AM, Tetzlaff W, Cuello AC. NGF prevents further atrophy of cholinergic cells of the nucleus basalis due to cortical infarction in adult post-hypothyroid rats but does not restore cell size compared to euthyroid [correction of euthroid] rats. J Chem Neuroanat 12(1): 15-27 (1996).
158. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 146(1): 91-103 (1997).
159. Ginsberg SD, Che S, Wuu J, Counts SE, Mufson EJ. Down regulation of trk but not p75NTR gene expression in single cholinergic basal forebrain neurons mark the progression of Alzheimer's disease. J Neurochem 97(2): 475-487 (2006).
160. Counts SE, Nadeem M, Wuu J, Ginsberg SD, Saragovi HU, Mufson EJ. Reduction of cortical TrkA but not p75(NTR) protein in early-stage Alzheimer's disease. Ann Neurol 56 (4): 520-531 (2004).
161. Fortress AM, Buhusi M, Helke KL, Granholm AC. Cholinergic degeneration and alterations in the TrkA and p75NTR balance as a result of Pro-NGF injection into aged rats. J Aging Res 2011: 460543 (2011).
162. Mufson EJ, He B, Nadeem M, Perez SE, Counts SE, Leurgans S, et al. Hippocampal proNGF signaling pathways and beta-amyloid levels in mild cognitive impairment and Alzheimer disease. J Neuropathol Exp Neurol 71 (11):1018-1029 (2012).
163. Phillips HS, Hains JM, Armanini M, Laramee GR, Johnson SA, Winslow JW. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron 7 (5): 695-702 (1991).
164. Connor B, Young D, Yan Q, Faull RL, Synek B, Dragunow M. Brain-derived neurotrophic factor is reduced in Alzheimer's disease. Brain Res Mol Brain Res 49(1-2): 71-81 (1997).
165. Holsinger RM, Schnarr J, Henry P, Castelo VT, Fahnestock M. Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease. Brain Res Mol Brain Res 76(2): 347-354 (2000).
166. Hock C, Heese K, Hulette C, Rosenberg C, Otten U. Regionspecific neurotrophin imbalances in Alzheimer disease: decreased levels of brain-derived neurotrophic factor and increased levels of nerve growth factor in hippocampus and cortical areas. Arch Neurol 57 (6): 846-851 (2000).
167. Garzon D, Yu G, Fahnestock M. A new brain-derived neurotrophic factor transcript and decrease in brain-derived neurotrophic factor transcripts 1, 2 and 3 in Alzheimer's disease parietal cortex. J Neurochem 82(5): 1058-1064 (2002).
168. Ferrer I, Marin C, Rey MJ, Ribalta T, Goutan E, Blanco R, et al. BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 58(7): 729-739 (1999).
169. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem 89(3): 312-323 (2008).
170. Lott IT, Dierssen M. Cognitive deficits and associated neurological complications in individuals with Down's syndrome. Lancet Neurol 9(6): 623-633 (2010).
171. Teipel SJ, Alexander GE, Schapiro MB, Moller HJ, Rapoport SI, Hampel H. Age-related cortical grey matter reductions in nondemented Down's syndrome adults determined by MRI with voxelbased morphometry. Brain 127(Pt 4): 811-824 (2004).
172. Raz N, Torres IJ, Briggs SD, Spencer WD, Thornton AE, Loken WJ, et al. Selective neuroanatomic abnormalities in Down's syndrome and their cognitive correlates: evidence from MRI morphometry. Neurology 45(2): 356-366 (1995).
173. Golden JA, Hyman BT. Development of the superior temporal neocortex is anomalous in trisomy 21. J Neuropathol Exp Neurol 53(5): 513-520 (1994).
174. Ross MH, Galaburda AM, Kemper TL. Down's syndrome: is there a decreased population of neurons? Neurology 34 (7):909-916 (1984).
175. Rissman RA, Mobley WC. Implications for treatment: GABAA receptors in aging, Down syndrome and Alzheimer's disease. J Neurochem 117(4): 613-622 (2011).
176. Mann DM, Yates PO, Marcyniuk B, Ravindra CR. The topography of plaques and tangles in Down's syndrome patients of different ages. Neuropathol Appl Neurobiol 12(5): 447-457 (1986).
177. Zigman WB, Devenny DA, Krinsky-McHale SJ, Jenkins EC, Urv TK, Wegiel J, et al. Alzheimer's disease in adults with down syndrome. Int Rev Res Ment Retard 36: 103-145 (2008).
178. Jervis GA. Early senile dementia in mongoloid idiocy. Am J Psychiatry 105(2): 102-106 (1948).
179. Busciglio J, Pelsman A, Wong C, Pigino G, Yuan M, Mori H, et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33(5): 677-688 (2002).
180. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun 122(3): 1131-1135 (1984).
181. Iulita MF, Do Carmo S, Ower AK, Fortress AM, Aguilar LF, Hanna M, et al. Nerve growth factor metabolic dysfunction in Down's syndrome brains. Brain 137(Pt 3): 860-872 (2014).
182. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93(23): 13333-13338 (1996).
183. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc Natl Acad Sci USA 98(18): 10439-10444 (2001).
184. Hunter CL, Isacson O, Nelson M, Bimonte-Nelson H, Seo H, Lin L, et al. Regional alterations in amyloid precursor protein and nerve growth factor across age in a mouse model of Down's syndrome. Neurosci Res 45(4): 437-445 (2003).
185. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, et al. Increased App expression in a mouse model of Down's syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51(1): 29-42 (2006).
186. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367(9): 795-804 (2012).
187. Villemagne VL, Burnham S, Bourgeat P, Brown B, Ellis KA, Salvado O, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol 12(4): 357-367 (2013).
188. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 256(3): 183-194 (2004).
189. Bennett DA, Wilson RS, Schneider JA, Evans DA, Beckett LA, Aggarwal NT, et al. Natural history of mild cognitive impairment in older persons. Neurology 59(2): 198-205 (2002).
190. Boyle PA, Wilson RS, Aggarwal NT, Tang Y, Bennett DA. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67(3): 441-445 (2006).
191. Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, et al. Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol 65(2): 176-183 (2009).
192. De Meyer G, Shapiro F, Vanderstichele H, Vanmechelen E, Engelborghs S, De Deyn PP, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 67(8): 949-956 (2010).
193. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3): 228-234 (2006).
194. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69(1): 98-106 (2012).
195. Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, et al. Longitudinal cerebrospinal fluid biomarkers over four years in mild cognitive impairment. J Alzheimers Dis 30(4): 767-778 (2012).
196. Peng S, Wuu J, Mufson EJ, Fahnestock M. Increased proNGF levels in subjects with mild cognitive impairment and mild Alzheimer disease. J Neuropathol Exp Neurol 63(6): 641-649 (2004).
197. Bruno MA, Mufson EJ, Wuu J, Cuello AC. Increased matrix metalloproteinase 9 activity in mild cognitive impairment. J Neuropathol Exp Neurol 68(12): 1309-1318 (2009).
198. Hanzel CE, Iulita MF, Eyjolfsdottir H, Hjorth E, Schultzberg M, Eriksdotter M, et al. Analysis of matrix metallo-proteases and the plasminogen system in mild cognitive impairment and Alzheimer's disease cerebrospinal fluid. J Alzheimers Dis 40(3): 667-678 (2014).
199. Nielsen HM, Minthon L, Londos E, Blennow K, Miranda E, Perez J, et al. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69(16): 1569-1579 (2007).
200. Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F, et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 69(1): 96-104 (2012).
201. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 21(3): 383-421 (2000).
202. Ferretti MT, Bruno MA, Ducatenzeiler A, Klein WL, Cuello AC. Intracellular Abeta-oligomers and early inflammation in a model of Alzheimer's disease. Neurobiol Aging 33 (7): 1329-1342 (2012).
203. Ferretti MT, Cuello AC. Does a pro-inflammatory process precede Alzheimer's disease and mild cognitive impairment? Curr Alzheimer Res 8(2): 164-174 (2011).
204. Hanzel CE, Pichet-Binette A, Pimentel LS, Iulita MF, Allard S, Ducatenzeiler A, et al. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging 35(10): 2249-2262 (2014).
205. Wilcock DM. Neuroinflammation in the aging down syndrome brain; lessons from Alzheimer's disease. Curr Gerontol Geriatr Res 2012: 170276 (2012).
206. Gottschall PE, Yu X, Bing B. Increased production of gelatinase B (matrix metalloproteinase-9) and interleukin-6 by activated rat microglia in culture. J Neurosci Res 42(3): 335-342 (1995).
207. Gu Z, Kaul M, Yan B, Kridel SJ, Cui J, Strongin A, et al. Snitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death. Science 297(5584): 1186-1190 (2002).
208. Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol 152(3): 729-741 (1998).
209. Belrose JC, Masoudi R, Michalski B, Fahnestock M. Increased pronerve growth factor and decreased brain-derived neurotrophic factor in non-Alzheimer's disease tauopathies. Neurobiol Aging 35(4): 926-933 (2014).
210. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hatanpaa KJ, et al. Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathol 114(1): 5-22 (2007).
211. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258 (5080): 304-307 (1992).